Apellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results

Apellis Pharmaceuticals (NASDAQ:APLS) announced its earnings results on Friday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.08, Zacks reports. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $212.50 million during the quarter, compared to analyst estimates of $197.92 million. During the same quarter in the previous year, the business earned ($0.73) earnings per share. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock traded down $1.08 on Friday, reaching $24.93. The company’s stock had a trading volume of 1,288,485 shares, compared to its average volume of 1,748,307. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The company has a market capitalization of $3.10 billion, a P/E ratio of -12.21 and a beta of 0.96. The stock has a 50-day moving average price of $30.04 and a 200-day moving average price of $31.62. Apellis Pharmaceuticals has a 52-week low of $24.33 and a 52-week high of $66.00.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $26.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, January 29th. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Scotiabank decreased their price objective on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a report on Wednesday, November 6th. Robert W. Baird dropped their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Finally, Morgan Stanley began coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price target for the company. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, insider Caroline Baumal sold 2,816 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the sale, the insider now owns 55,560 shares of the company’s stock, valued at $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Cedric Francois sold 6,247 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90. Following the transaction, the chief executive officer now owns 307,415 shares in the company, valued at $8,822,810.50. The trade was a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 60,365 shares of company stock valued at $1,810,479 over the last ninety days. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).